COVID-19 mRNA vaccine - PopVax
Alternative Names: mRNA-LNP COVID-19 VaccineLatest Information Update: 05 Dec 2024
Price :
$50 *
At a glance
- Originator PopVax
- Class COVID-19 vaccines; RNA vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 13 Nov 2024 Preclinical trials in COVID-2019 infections (Prevention) in India (Unspecified) before November 2024
- 13 Nov 2024 Immunogenicity data from a preclinical trial in COVID-2019 infections released by PopVax
- 13 Nov 2024 PopVax in collaboration with National Institute of Allergy and Infectious Diseases plans a phase I first-in-human trial for COVID-2019 infections (Prevention) in USA (Parenteral) in early 2025